April 19, 2014

Big Pharma’s Newest Money-Making Scheme: Adult ADHD

Many Pills Big Pharmas Newest Money Making Scheme: Adult ADHD

By Evelyn Pringle and Martha Rosenberg
AlterNet.com 

Who belongs to this “untapped” market? Just about anybody.

There is good news and bad news about attention deficit/hyperactivity disorder (ADHD) — that is, if you’re a drug company. The bad news is the kid market has peaked out with 4.5 million U.S. children now carrying the label. The good news is adult ADHD is an emerging market. In fact, adult ADHD, with symptoms similar to pediatric ADHD such as impulsivity, distractibility and difficulty paying attention, following instructions and meeting deadlines, is the next big thing.

“Immature adult market continues to offer greatest commercial potential,” read a 2008 press release to the pharmaceutical industry from the market research agency Datamonitor: “Estimated to be twice the size of the pediatric ADHD population, the highly prevalent, yet largely untapped, adult ADHD population continues to represent an attractive niche to target.”

So who might consider themselves part of this “untapped” market?

Like astrology in which anyone relates to Scorpio’s horoscope, almost everyone who takes an adult ADHD quiz will discover they are “sick.” To qualify as having attention deficit/hyperactivity disorder according to the most recent draft of the American Psychiatric Association’s DSM-5, soon to be published, you need to suffer from six or more of the following symptoms for at least six months:

Click here to continue reading: http://www.alternet.org/personal-health/big-pharmas-newest-money-making-scheme-adult-adhd


0 commentsback to post

Other articlesgo to homepage

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

Congressman Bill Posey’s strong resolve and demands for transparency were evident as he discussed the Center for Disease Control (CDC)’s handling of vaccine safety studies which affect “our most precious resource in our nation – our children.” The 30-minute interview, conducted by vaccine industry watchdog, PhD biochemist Brian Hooker, delves into what Posey called “the incestuous relationship between the public health community and the vaccine makers and public officials.”

The Florida legislator, known as “Mr. Accountabililty,” did not mince words when criticizing current and past CDC officials including indicted fraudster Dr. Poul Thorsen; CDC director turned Merck Vaccine President Dr. Julie Gerberding; and the agency’s current spokesperson regarding autism and vaccines, Dr. Coleen Boyle.

Congressman Posey said, “The CDC can’t be trusted regarding investigating vaccine safety. Huge conflict of interest. I think the CDC should be investigated.”

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

In an interview with Dr. Bernard Dalbergue, a former pharmaceutical industry physician with Gardasil manufacturer Merck, he predicts that Gardasil will become the greatest medical scandal of all time. Dr. Dalbergue believes that at some point in time, the evidence will add up to prove that this vaccine, technical and scientific feat that it may be, has absolutely no effect on cervical cancer and that all the very many adverse effects which destroy lives and even kill young girls, serves no other purpose than to generate profit for the manufacturers.

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

An important new book by a recognized medical research expert describes Big Pharma as akin to the Mafia. In an interview conducted by our colleagues at ANH-Europe, Dr. Peter C. Gøtzsche exposes the flaws of the drug approval system, our reliance on dangerous drugs, and the deadly co-dependence between regulators and industry. Dr. Gøtzsche is co-founder of the highly respected Cochrane Collaboration and Cochrane Reviews, a leading journal of evidence-based medicine. The interview is particularly timely now that the FDA has decided to remove restrictions on the dangerous drug Avandia.

Dr. Gøtzsche’s new book, Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare, points out that the pharmaceutical industry is allowed to test their own drugs, and thus effectively be their own judge. He calls this a threat to safe medicine and asks for open access to all research data, including raw data, because otherwise, data can be easily suppressed and conclusions manipulated by industry.

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical marijuana, or cannabis, is legal in 20 US states, where it is used for a variety of medical conditions such as mood disorders, pain disorders, multiple sclerosis, and even cancer. Parents of children with epilepsy met at a news conference to share their dismay that Governor Mark Dayton refuses to legalize medical marijuana. About 85 percent to 95 percent of Americans are in favor of medical cannabis, and nearly 60 percent are in favor of legalizing marijuana. Cannabis shows outstanding promise as a medicinal plant, largely due to its cannabidiol (CBD) content. Cannabinoids interact with your body by way of naturally occurring cannabinoid receptors embedded in cell membranes throughout your body.

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Pharmaceutical company payments to doctors extend far beyond rank-and-file clinicians — and deep into the leadership of America’s teaching hospitals, according to a study published recently in the Journal of the American Medical Association.

A team of researchers at the University of Pittsburgh Medical Center examined the boards of the 50 largest drug companies by global sales (excluding three companies that were not publicly traded). The researchers found that 40 percent — 19 companies — had at least one board member who also held a leadership role at an academic medical center. Sixteen of the 17 companies based in the United States had at least one. Several had more than one. All told, the research team found that 41 of the companies’ 2012 board members held leadership positions at academic medical centers. Six of the 41 were pharmaceutical company executives who served on hospital boards of directors or held other leadership posts.

The authors wrote that when academic medical leaders serve on pharmaceutical company boards, it can lead to conflicts not only for individuals, but for the critically important health care institutions they guide.

read more


Get the news right in your inbox!